EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome



Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome



Clinical Nephrology 67(5): 285-292



Single daily dose cyclosporine (SDD-CsA) might be a new option providing comparable efficacy, increased compliance and less nephrotoxicity compared to standard twice-daily dose cyclosporine (TDD-CsA). The aim of this trial was to prove the feasibility of SDD-CsA as primary and secondary maintenance therapy in patients with nephrotic syndrome. We treated 25 adult patients with nephrotic syndrome and chronic primary glomerulonephropathy with SDD-CsA for a period of 12 months or more. 12 patients were pre-treated with twice-daily dose cyclosporine (TDD-CsA) and were then switched secondarily to a single daily dose after a median period of 8 months (sSDD-CsA). 13 patients were treated primarily with single daily dose cyclosporine (pSDD-CsA). In primary SDD-CsA patients, proteinuria decreased significantly from 9.2 - 0.8 g/l (p = 0.02) and serum protein increased significantly from 54 - 71 g/l (p = 0.03) during the study period. In secondary SDD-CsA patients, serum protein increased further (64 - 69, p = 0.04) after switching to SDD-CsA. In secondary SDD-CsA patients, the median total daily CsA dose was significantly lower (200 mg) with SDD-CsA compared to previous twice-daily dosing (300 mg, p = 0.01). Serum creatinine did not differ significantly before and after therapy and between the groups. SDD-CsA is effective in patients with nephrotic syndrome as primary and secondary maintenance therapy. SDD-CsA allows for significantly lower total daily doses, probably with less nephrotoxicity.

(PDF 0-2 workdays service: $29.90)

Accession: 055793668

Download citation: RISBibTeXText

PMID: 17542337



Related references

Is single-daily low-dose cyclosporine therapy really effective in children with idiopathic frequent-relapsing nephrotic syndrome?. Clinical Nephrology 69(2): 84-89, 2008

Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatric Nephrology 26(3): 479-483, 2011

Daily single-dose and daily reduced-dose prednisone therapy for children with the nephrotic syndrome. Pediatrics 83(5): 694-699, 1989

C1-C2 point monitoring of low-dose cyclosporin a given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Clinical Nephrology 64(4): 258-263, 2005

Single daily dose cyclosporin in nephrotic syndrome in adults. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 675A, September, 2002

Single-dose daily administration of cyclosporin A for relapsing nephrotic syndrome. Pediatric Nephrology 19(9): 1055-1058, 2004

Single-dose daily administration of cyclosporin A for refractory nephrotic syndrome. Pediatric Nephrology 20(7): 1021-1022, 2005

Daily single dose prednisolone therapy in steroid responsive nephrotic syndrome. Pediatric Nephrology 6(5): C135, 1992

Daily single-dose and long-term prednisone therapy for child simple nephrotic syndrome. Hunan Yike Daxue Xuebao 18(4): 469-470, 1993

Single-dose daily treatment with cyclosporin A for relapsing nephrotic syndrome: report of a case showing poor response. Clinical Nephrology 66(3): 219-220, 2006

Glucagon secretion in patients with nephrotic syndrome in primary glomerulonephritis during the period of renal efficiency. Annales Academiae Medicae Stetinensis 36: 113-132, 1990

Using extra-high cyclophosphamide doses in treatment of primary glomerulonephritis patients with nephrotic syndrome. Nephrology Dialysis Transplantation 12(9): A75, 1997

Triple therapy with single daily dose of cyclosporine in Japanese patients with idiopathic membranous nephropathy. Internal Medicine 50(18): 1905-1910, 2012

The response to immunosuppressive treatment in patients with primary glomerulonephritis and nephrotic syndrome and the changes in urinary NAG, TGFbeta and MCP-1 excretions. Journal of the American Society of Nephrology 14(Abstracts Issue): 800A, November, 2003

Nephrotic primitive syndrome due to steroid-dependent mesangioproliferative glomerulonephritis treated with low doses of cyclosporine A. Nephrology Dialysis Transplantation 12(9): A75, 1997